Dulanermin
A detailed overview of Dulanermin, a recombinant protein used in cancer therapy research.
Dulanermin is a recombinant protein that mimics the activity of the naturally occurring tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). It is designed to induce apoptosis in cancer cells, making it a potential therapeutic agent in oncology.
Mechanism of Action[edit | edit source]
Dulanermin functions by binding to death receptors DR4 (TRAIL-R1) and DR5 (TRAIL-R2) on the surface of cancer cells. This binding triggers the extrinsic apoptotic pathway, leading to programmed cell death. The selectivity of Dulanermin for cancer cells over normal cells is attributed to the differential expression of these receptors.
Clinical Development[edit | edit source]
Dulanermin has been evaluated in several clinical trials for its efficacy and safety in treating various types of cancer, including non-small cell lung cancer (NSCLC) and colorectal cancer. Early-phase trials have shown that Dulanermin can be administered safely, with some evidence of anti-tumor activity.
Phase I Trials[edit | edit source]
Initial Phase I trials focused on determining the maximum tolerated dose and assessing the pharmacokinetics of Dulanermin. These studies indicated that Dulanermin was well-tolerated, with manageable side effects such as fatigue and nausea.
Phase II Trials[edit | edit source]
Subsequent Phase II trials aimed to evaluate the efficacy of Dulanermin in combination with other chemotherapeutic agents. Results have been mixed, with some studies showing enhanced anti-tumor effects, while others did not demonstrate significant improvements over standard therapies.
Challenges and Future Directions[edit | edit source]
Despite its potential, the clinical development of Dulanermin has faced challenges, including the development of resistance in some cancer types and variability in patient response. Future research is focused on identifying biomarkers that predict response to Dulanermin and developing combination therapies to overcome resistance.
Also see[edit | edit source]
- Tumor necrosis factor-related apoptosis-inducing ligand
- Apoptosis
- Cancer therapy
- Recombinant proteins
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
